4.4 Patient Navigation & Interprofessional Care Coordination
Key Takeaways
- Multidisciplinary Tumor Boards (MDTBs) integrate surgical, medical, and radiation oncology with pathology, radiology, and APRN navigators to formulate individualized, guideline-adherent treatment plans.
- Advanced Practice Registered Nurses (APRNs) serve as critical coordinators across transition points (diagnosis, active treatment, survivorship, end-of-life), reducing time-to-treatment initiation and emergency department visits.
- Formal PCP treatment summaries and survivorship handoff communication bridge care gaps, ensuring routine preventive care, chronic disease management, and cancer surveillance are clearly assigned.
- Comprehensive barrier-to-care assessments evaluate social determinants of health (SDOH), financial toxicity, transportation, and health literacy to trigger timely navigation and social work referrals.
- Telehealth integration enhances continuity of care in rural and underserved oncology populations, enabling remote symptom monitoring, oral antineoplastic adherence tracking, and multidisciplinary care consultations.
2.3 Continuity of Care & Multidisciplinary Care Coordination
Clinical Pearl: Seamless care coordination across multidisciplinary teams improves time-to-treatment initiation, adherence to NCCN clinical practice guidelines, patient satisfaction, and overall survival. The oncology APRN bridges subspecialty silos, translating complex molecular diagnostics and multimodal treatment plans into actionable care pathways.
Multidisciplinary Care Models & Tumor Boards
Modern oncology care delivery relies on a coordinated multidisciplinary care model. The cornerstone of this framework is the Multidisciplinary Tumor Board (MDTB), a prospective clinical forum where subspecialist experts review diagnostic findings, staging, and therapeutic options to establish consensus treatment plans for complex cancer cases.
Key Tumor Board Participants & Roles
- Medical Oncology: Evaluates candidate systemic therapies (chemotherapy, targeted agents, immunotherapies, hormonal agents) and clinical trial eligibility.
- Surgical Oncology: Assesses surgical resectability, organ preservation strategies, surgical margins, and reconstructive options.
- Radiation Oncology: Defines radiation modalities (IMRT, SBRT, proton therapy), field margins, total gray (Gy) dosing, and concurrent systemic sensitizers.
- Pathology & Molecular Diagnostics: Reviews tissue histology, immunohistochemical (IHC) markers, fluorescent in situ hybridization (FISH), and genomic alteration panels (NGS).
- Diagnostic & Interventional Radiology: Re-evaluates staging imaging (CT, PET/CT, MRI) and determines suitability for image-guided biopsies or interventional liver-directed therapies.
- Oncology APRN / Nurse Navigator: Synthesizes patient functional status (ECOG/Karnofsky), baseline comorbidities, organ function reserve, psychosocial barriers, and personal goals of care to ensure recommendations are clinically feasible and patient-centered.
Vulnerable Care Transition Nodes
Care transitions represent high-risk windows for communication failures, diagnostic delays, medication errors, and distress. The APRN mitigates risk at four key transition nodes:
| Care Transition Node | Major Vulnerabilities & Care Gaps | APRN Navigation Interventions |
|---|---|---|
| 1. Diagnosis → Active Treatment | Anxiety, insurance pre-authorization delays, uncoordinated multi-subspecialty consultations, diagnostic testing duplication | Expedite staging workups; coordinate multi-specialty visits in single-day blocks; complete pre-treatment organ toxicity baselines |
| 2. Inpatient → Outpatient Infusion | Unmanaged acute toxicities, medication reconciliation errors, inadequate home supportive medications | Standardize discharge handoffs; verify outpatient antiemetic prescriptions; conduct post-discharge phone calls within 48–72 hours |
| 3. Active Treatment → Survivorship | Loss of safety net feelings, persistent symptom distress, unassigned surveillance tasks, lack of PCP communication | Deliver Survivorship Care Plan (SCP); conduct end-of-treatment exit consultation; transfer formal treatment summary to PCP |
| 4. Disease Progression → Palliative / Hospice | Reluctance to transition care goals, delayed hospice referrals, unmanaged crisis pain, caregiver burden | Initiate early palliative care integration; conduct goals-of-care discussions; coordinate hospice handoffs & symptom kits |
Primary Care Integration & Shared-Care Models
As cancer survivorship expands, oncology specialists cannot sole-manage all long-term health needs. Shared-care models formalize collaboration between oncology APRNs and Primary Care Providers (PCPs).
┌─────────────────────────────────────────┐
│ Oncology APRN / Specialist Team │
│ - Cancer Recurrence Surveillance │
│ - Specialized Late Effects Management │
│ - Molecular/Targeted Therapy Monitoring │
└────────────────────┬────────────────────┘
│
Shared-Care Model
(Formal SCP Handoff)
│
┌────────────────────┴────────────────────┐
│ Primary Care Provider (PCP) │
│ - Routine Health Maintenance & Vaccine │
│ - Comorbidity (HTN, DM, Dyslipidemia) │
│ - General Cancer Screening (CRC, Pap) │
└─────────────────────────────────────────┘
Principles of Effective PCP Handoff Communication
- Explicit Division of Responsibility: Document which provider orders surveillance imaging (e.g., oncology orders annual mammogram/breast MRI; PCP handles cervical/colon cancer screening).
- Management of Co-morbidities: Ensure pre-existing hypertension, diabetes, and cardiovascular disease are actively managed during and after cardiotoxic or anti-angiogenic antineoplastic therapies.
- Vaccination & Immunization Protocols: Outline safe vaccination timing (inactivated vaccines recommended post-chemotherapy; live-attenuated vaccines contraindicated during active immunosuppression and for 3–6 months post-chemotherapy/biologic therapy).
Addressing Social Determinants of Health (SDOH) & Financial Toxicity
Financial Toxicity in Oncology
Financial toxicity describes the severe financial distress and out-of-pocket burden experienced by cancer patients. High copayments for novel oral antineoplastics (e.g., TKIs, PARP inhibitors, CDK4/6 inhibitors) lead to non-adherence, drug rationing, and treatment abandonment.
- APRN Action: Routinely screen for financial distress using validated instruments (e.g., COST measure). Refer patients proactively to oncology financial navigators, pharmaceutical Patient Assistance Programs (PAPs), co-pay assistance foundation grants, and social work services before treatment delays occur.
Health Literacy & Language Barriers
Complex oncology terminology hinders informed decision-making. APRNs utilize the Teach-Back Method, plain-language educational materials, certified medical interpreters (avoiding family members for clinical consent), and culturally tailored resources.
Telehealth & Community-Academic Care Coordination
Telehealth has emerged as an indispensable modality for preserving continuity of care, particularly for rural and medically underserved populations.
- Remote Patient Monitoring (RPM): Digital symptom tracking applications enable real-time patient reporting of toxicities (e.g., fever, diarrhea, CIPN, nausea). Automated alerts notify the APRN, prompting early outpatient intervention and reducing emergency department visits by up to 20%.
- Community-Academic Partnerships (NCORP): The NCI Community Oncology Research Program (NCORP) links community oncology practices with academic medical centers. APRNs facilitate local enrollment into national clinical trials, allowing patients to receive cutting-edge protocols near home while maintaining centralized multidisciplinary protocol oversight.
Which intervention represents the primary role of the oncology Advanced Practice Registered Nurse (APRN) during a Multidisciplinary Tumor Board (MDTB) presentation?
A patient diagnosed with metastatic renal cell carcinoma is prescribed an oral tyrosine kinase inhibitor but reports being unable to afford the $3,000 monthly copayment. What is the most appropriate initial action by the oncology APRN to prevent treatment delay?
In a shared-care survivorship model between an oncology practice and a primary care provider (PCP), how should care responsibilities be delineated to ensure optimal continuity of care?